Background
==========

Antineutrophil cytoplasmic antibodies (ANCA)-associated systemic vasculitides are a group of small vessel vasculitic syndromes including Wegener\'s granulomatosis, microscopic polyangiitis and Churg Strauss syndrome. These diseases share a common pathology with focal necrotizing lesions that affect different vessels and organs. Wegener\'s granulomatosis and Churg Strauss syndrome have additional granulomatous lesions. They have a variety of presentations, but cardiac valvular involvement is rarely reported.

In this report we describe the case of a patient with an ANCA associated systemic vasculitis who presented with aortic regurgitation of unusual mechanism requiring surgical replacement.

Case report
===========

The patient was a 44-year-old man from Bangladesh who immigrated to France twenty years ago and worked in several dusty embroidery workshops. Eight months prior to his admission in our hospital, he developed right chronic headaches resisting usual painkillers with right hypoacusia and tinnitus. The right ear examination was consistent with chronic otitis media. A sinus CT scan showed pansinusitis predominating on the right side with right mastoiditis and otitis media. A cerebral MRI showed pachymeningitis of the cerebellopontine angle. Right myringotomy yielded culture-negative drainage. The patient underwent several unsuccessful antibiotic treatments.

Eight months after the onset of the disease, the patient was referred to our ward, complaining, in addition to the other symptoms, of signs of severe intracranial hypertension (persistant right headaches and vomiting), significant weight loss, and a change in his voice. Otorhinological examination showed an unchanged right ear, a paralysis of the left vocal cord responsible for the dysphonia, an abolition of the gag reflex, and a palatal paralysis. The blood pressure was 140/65 mmHg, the heart rate of 75 bpm and the general examination was normal aside from a three out of four diastolic murmur of aortic regurgitation, without any other cardiac signs and a normal electrocardiogram.

An abdominal CT-scan showed a focal thickening of the aortic arch and an identical thickening of the superior mesenteric vein, interpreted as focal aortic and mesenteric vasculitis. A mesenteric panniculitis was also apparent. Laboratory studies included the following values: C-reactive protein 35 mg/l, serum urea nitrogen 4.6 mM/l, creatinine 86 mcM/l, total leukocyte count 10.3 × 10\^9/l, polyclonal hypergammaglobulinemia, negative antiphospholipid antibodies, positive antineutrophil cytoplasmic antibodies (ANCA) with positive antimyeloperoxidase antibodies and negative antiproteinase 3 antibodies. The cerebrospinal fluid contained 60 cells per mm3 with 28% lymphocytes and 1.11 g/l of protein; the bacterial, fungal and mycobacterial cultures were negative. The cerebral MRI performed on admission was unchanged. Inferior nasal concha biopsies showed nonspecific inflammation; temporal artery biopsies were normal. Transthoracic and transesophageal echocardiography revealed septal hypertrophy leading to a restriction of aortic valvular closure and thus to massive aortic regurgitation (Figure [1](#F1){ref-type="fig"}).

![**Transesophageal echocardiography showing septal hypertrophy (white arrows) and lack of central coaptation of aortic valve (yellow arrows), resulting in massive aortic regurgitation**. Ao = aorta. LA = left atrium. LV = left ventricle.](1471-2474-12-50-1){#F1}

The presumptive diagnosis was ANCA-associated systemic vasculitis, most probably Wegener\'s granulomatosis, with aortic valvular involvement. Treatment with prednisone (1 mg/kg) and intravenous cyclophosphamide (700 mg/m2 every two weeks during one month then every four weeks) was started. With this immunosuppressive therapy the palatal paralysis subsided, the headaches lessened and the patient, slowly regaining weight and energy, was able to return home.

Four months after the beginning of treatment there was an absence of echocardiographic improvement of the septal hypertrophy and aortic regurgitation and the patient had developed congestive heart failure, so the decision was made to perform an aortic Bicarbon™valve replacement. Upon inspection, the aorta wall and the aortic valve leaflets appeared diffusely thickened. There was a focal thickening of the interventricular septum covered with fibrous tissue. Fibrous tissue was also found on the aortic ring and on the large mitral leaflet. No vegetations were seen. At the end of surgery the patient was in persistent complete heart block requiring a pacemaker implantation.

The microscopic examination of the septum showed chronic remodelling with fibrous and hyaline tissue, and an intense polymorphic inflammatory infiltrate. Fibrosis as well as a local fragmentation of the elastic fibers was found in the intima and media of the aortic wall. No inflammatory infiltrate nor granuloma were seen in the aortic specimens.

Two years after surgery, the patient is doing well on azathioprine (see Table [1](#T1){ref-type="table"}).

###### 

Symptoms, severity score index and main lab and imagery results of the patient described in the case report.

  November 2006   \- Persisting facial pain, right chronic headaches resisting usual pain killers
  --------------- -----------------------------------------------------------------------------------------------------------
  March 2007      \- Same symptoms + right hypoacusia and tinnitus
                  \- Cerebral CT-scan: pansinusitis predominating on the right side with right mastoiditis and otitis media
                  \- Cerebral MRI: pachymeningitis of the cerebellopontine angle
                  
  June 2007       When hospitalized:
                   - Violent headaches and vomiting: severe intracranial hypertension
                   - Significant weight loss (- 10 kg)
                   - Right otitis media
                   - Paralysis of the left vocal cord (dysphonia), abolition of the gag reflex, and palatal paralysis
                   - Cerebral MRI: unchanged
                   - Spinal tap: Aseptic meningitis
                   - Discovery of the aortic regurgitation
                   - Abdominal CT-scan: focal aortic and mesenteric vasculitis and mesenteric panniculitis
                   - Elevated C-reactive protein and leukocyte count
                   - Polyclonal hypergammaglobulinemia
                   - pANCA+; anti-MPO +; anti Pr3 -
                   - BVAS = 23
                  
  June 2009       BVAS = 2

BVAS: Birmingham Vasculitis Activity Score

Discussion
==========

In this patient, the diagnosis of ANCA-associated systemic vasculitis, most probably Wegener\'s granulomatosis, was based on the association of pansinusitis, otitis, mastoiditis, chronic lymphocytic meningitis, aortitis and positive ANCA. This diagnosis was assessed at the National Referral Center for Rare Systemic and Autoimmune Diseases, Necrotizing Vasculitides, and Systemic Sclerosis (Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris-Descartes, Paris). Although Pr3-ANCA, found in 70 to 90% of patients with Wegener\'s granulomatosis, is often considered to be a seromarker of this disease, MPO-ANCA has been reported to be predominant in Asian patients \[[@B1]\]. This could explain the positive p-ANCA and negative c-ANCA in this patient who is from Bangladesh. The very unusual and unique feature in this patient was the particular mechanism of aortic valve involvement that required a valve replacement.

Using a Pubmed search we looked for reported cases of ANCA-associated systemic vasculitis with a valvular involvement, using the keywords \"valve\", \"cardiac\", \"heart\", \"endocarditis\", \"mitral\", \"aortic\", \"tricuspid\", \"pulmonary\", \"ANCA\", \"antineutrophil cytoplasmic antibodies\", \"Wegener\'s granulomatosis\", \"microscopic polyangiitis\" and \"Churg Strauss\" in different combinations. We completed this search by cross-referencing published articles. We thus selected 19 articles in English reporting 20 cases consistent with a systemic ANCA-associated vasculitis with endocardial valvular involvement, i.e. valvular lesions for which infective endocarditis had been excluded and no other aetiology found \[[@B2]-[@B20]\].

The general characteristics of the patients and of their vasculitides are reviewed in Table [2](#T2){ref-type="table"}. Their average age tends to be younger than that of the other patients presenting an ANCA-associated-vasculitis (40 versus 47 years old \[[@B21]\]) and the male predominance is greater (80% versus 53% \[[@B21]\]). One case excepted \[[@B19]\], all reported cases were diagnosed as Wegener\'s granulomatosis and presented with at least one of the three most common involvements, i.e. renal, pulmonary and otolaryngological. Eye, skin or joint involvement was present in about half the cases. Only 6 patients out of 20 experienced another cardiac lesion, such as pericardial effusion or adhesions \[[@B6],[@B10],[@B15]\], conduction disorders \[[@B4],[@B9],[@B10]\] and coronary artery stenosis \[[@B12]\].

###### 

General characteristics of patients with systemic vasculitides and valvular involvement.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                 Sex   Age   ANCA                   Vasculitis\                 Kidney   ENT   Organ\   Involvement\   Skin   Joints   Non-valvular\
                                                               Classification                             Lungs    Eyes                           cardiac lesion
  ------------------------- ----- ----- ---------------------- --------------------------- -------- ----- -------- -------------- ------ -------- ----------------
  Stöllberger \[[@B19]\]    M     56    ANCA -, anti-PR3 +     Unknown                     Yes      \-    \-       \-             Yes    Yes      \-

                                                                                                                                                  

  Levine \[[@B15]\]         M     28    **-**                  Wegener\'s granulomatosis   Yes      Yes   Yes      \-             \-     \-       Yes

                                                                                                                                                  

  Davenport \[[@B6]\]       M     19    c-ANCA +, anti-PR3 +   Wegener\'s granulomatosis   Yes      Yes   Yes      Yes            Yes    Yes      \-

                                                                                                                                                  

                            M     53    c-ANCA +, anti-PR3 +   Wegener\'s granulomatosis   Yes      \-    \-       \-             \-     \-       Yes

                                                                                                                                                  

  Grant \[[@B10]\]          M     32    c-ANCA +               Wegener\'s granulomatosis   \-       Yes   \-       Yes            Yes    Yes      Yes

                                                                                                                                                  

  Goodfield \[[@B9]\]       M     25    c-ANCA +               Wegener\'s granulomatosis   \-       Yes   Yes      \-             \-     \-       Yes

                                                                                                                                                  

  Bruno \[[@B4]\]           F     63    ANCA +                 Wegener\'s granulomatosis   \-       Yes   Yes      \-             \-     \-       Yes

                                                                                                                                                  

  Herbst \[[@B12]\]         F     56    ANCA -                 Wegener\'s granulomatosis   \-       \-    Yes      \-             \-     Yes      Yes

                                                                                                                                                  

  Gerbracht \[[@B8]\]       M     20    \-                     Wegener\'s granulomatosis   Yes      Yes   Yes      \-             \-     \-       \-

                                                                                                                                                  

  Greidinger \[[@B11]\]     M     15    c-ANCA +               Wegener\'s granulomatosis   Yes      Yes   Yes      \-             Yes    Yes      \-

                                                                                                                                                  

  Leff \[[@B14]\]           M     17    c-ANCA +               Wegener\'s granulomatosis   \-       Yes   Yes      \-             Yes    Yes      \-

                                                                                                                                                  

  Yanda \[[@B20]\]          F     77    \-                     Wegener\'s granulomatosis   Yes      Yes   Yes      Yes            Yes    \-       \-

                                                                                                                                                  

  Dabbagh \[[@B5]\]         M     16    \-                     Wegener\'s granulomatosis   Yes      Yes   Yes      Yes            \-     \-       \-

                                                                                                                                                  

  Fox \[[@B7]\]             M     20    ANCA +                 Wegener\'s granulomatosis   Yes      Yes   Yes      Yes            Yes    Yes      \-

                                                                                                                                                  

  Anthony \[[@B2]\]         M     48    c-ANCA +, anti-PR3 +   Wegener\'s granulomatosis   \-       Yes   Yes      \-             Yes    Yes      \-

                                                                                                                                                  

  Paik \[[@B17]\]           M     48    c-ANCA +               Wegener\'s granulomatosis   \-       Yes   Yes      \-             \-     \-       \-

                                                                                                                                                  

  Mishell \[[@B16]\]        M     65    ANCA +, anti-PR3 +     Wegener\'s granulomatosis   Yes      \-    Yes      Yes            Yes    \-       \-

                                                                                                                                                  

  Ramakrishnan \[[@B18]\]   F     44    c-ANCA +               Wegener\'s granulomatosis   Yes      \-    Yes      \-             \-     \-       \-

                                                                                                                                                  

  Attaran \[[@B3]\]         M     52    \-                     Wegener\'s granulomatosis   \-       Yes   \-       \-             \-     \-       \-

                                                                                                                                                  

  Koyalakonda \[[@B13]\]    M     52    \-                     Wegener\'s granulomatosis   \-       Yes   \-       Yes            \-     \-       \-

                                                                                                                                                  

  Present report            M     44    p-ANCA +, anti-PR3 -   Wegener\'s granulomatosis   \-       Yes   \-       \-             \-     \-       \-
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

ANCA: antineutrophil cytoplasmic antibodies; ENT: ear, nose and/or throat involvement; PR3: proteinase-3.

Table [3](#T3){ref-type="table"} details the characteristics of the valvular lesions in the 20 different cases. The most commonly encountered disorder is aortic regurgitation \[[@B4]-[@B11],[@B13],[@B14],[@B19],[@B20]\]. Seven cases of mitral regurgitation \[[@B3],[@B7],[@B11]-[@B13],[@B15],[@B20]\], and one of aortic stenosis \[[@B2]\] were also reported along with two cases of valvular vegetations \[[@B16],[@B17]\], two of a mass involving a mitral leaflet responsible for mild mitral stenosis and moderate mitral regurgitation \[[@B3],[@B13]\], and one of multiple atrial masses without valvular insufficiency or stenosis \[[@B18]\]. Six patients had polyvalvular involvement \[[@B3],[@B7],[@B11],[@B13],[@B16],[@B20]\]. Several mechanisms responsible for these valvular lesions have been reported: vegetations \[[@B2],[@B8],[@B16],[@B17],[@B19]\], leaflet thickening \[[@B4],[@B6],[@B9],[@B13],[@B20]\], valvular perforation \[[@B6],[@B14]\] and unique or multiple endocardial masses \[[@B3],[@B9],[@B12],[@B13],[@B18]\].

###### 

Valvular lesion characteristics in patients with systemic vasculitides.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                 Valve lesion onset                                Valve lesion            Mechanism of valvular disease                                                Valvular treatment   Outcome                                                                             Valve histology
  ------------------------- ------------------------------------------------- ----------------------- ---------------------------------------------------------------------------- -------------------- ----------------------------------------------------------------------------------- -----------------
  Stöllberger \[[@B19]\]    After 3 days steroïds                             AR                      Vegetation                                                                   \-                   AVR                                                                                 Non specific

  Levine \[[@B15]\]         After 6 weeks of ENT signs no IST                 MR                      ?                                                                            \-                   Died of heart failure                                                               \-

  Davenport \[[@B6]\]       At initial presentation                           AR                      Leaflet perforation and\                                                     1 year IST           AVR                                                                                 Non specific
                                                                                                      tissue disruption                                                                                                                                                                     

                            At initial presentation                           AR                      Thickened leaflets                                                           IST                  Worse, awaiting AVR                                                                 \-

  Grant \[[@B10]\]          After 1 year of CYC                               AR                      Dilation of ascending aorta                                                  20 Mo IST            AVR                                                                                 Non specific

  Goodfield \[[@B9]\]       At initial presentation                           AR                      Thickened leaflets and mass obstructing the left ventricular outflow tract   6 weeks IST          Thickening & mass disappeared. AVR because of LV dilatation & shrunken Ao leaflet   Non specific

  Bruno \[[@B4]\]           3 years after illness onset, no IST               AR                      Thickened, rigid and retracted leaflets                                      \_                   AVR                                                                                 Specific

  Herbst \[[@B12]\]         At initial presentation                           MR                      Mass involving a leaflet                                                                          MVR & AVR                                                                           Specific

  Gerbracht \[[@B8]\]       After 5 days CYC                                  AR                      Vegetation                                                                   IST                  Complete resolution                                                                 \-

  Greidinger \[[@B11]\]     After 3 weeks CYC                                 AR                      ?                                                                            IST                  Lesion unchanged                                                                    \-

                                                                              MR                      ?                                                                            IST                  Lesion unchanged                                                                    \-

  Leff \[[@B14]\]           At initial presentation                           AR                      Perforation of 2 leaflets                                                    1 year IST           Ao valve repair: homograft                                                          \-

  Yanda \[[@B20]\]          1 year after initial presentation,\               AR                      Thickened leaflet                                                            \-                   AVR                                                                                 Non specific
                            no IST                                                                                                                                                                                                                                                          

                                                                              MR                      Thickened leaflet                                                            IST                  ?                                                                                   \-

  Dabbagh \[[@B5]\]         After 3 weeks CYC                                 AR                      ?                                                                            IST                  ?                                                                                   \-

  Fox \[[@B7]\]             At initial presentation                           AR                      Prolapsing Ao leaflets and discrete Ao leaflet deficiency                    5 Mo IST             AVR                                                                                 Non specific

                                                                              MR                      ?                                                                            IST                  ?                                                                                   \-

  Anthony \[[@B2]\]         At initial presentation                           AS                      Vegetation                                                                   3 Mo IST             Lesion unchanged                                                                    \-

  Paik \[[@B17]\]           At initial presentation                           Ao vegetations          Vegetation                                                                   IST                  ?                                                                                   

  Mishell \[[@B16]\]        At initial presentation                           Ao and M vegetations    Vegetations                                                                  IST                  Died                                                                                Non specific

  Ramakrishnan \[[@B18]\]   At initial presentation                           M masses                Multiple masses in atriums and on MP                                         Few days IST         Died                                                                                \-

  Attaran \[[@B3]\]         30 years after illness onset, IST?                Ao and M mass, MR, MS   Mass involving an Ao and an M leaflet                                        IST                  MVR & AVR                                                                           Non specific

  Koyalakonda \[[@B13]\]    Not at initial presentation and under treatment   MS & MR\                M mass involving leaflet\                                                    IST\                 Mass unchanged: MVR\                                                                Non specific
                                                                              AR                      Thickened Ao valve                                                           IST                  AR progressed: AVR                                                                  

  Present report            At initial presentation                           AR                      Septal thickening: incomplete closure of Ao valve, thickened leaflets        4 Mo IST             AVR                                                                                 Non specific
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

?: Unknown; AR: aortic regurgitation; Ao: aortic; AS: aortic stenosis; AVR: aortic valve replacement; CYC: cyclophosphamide; IST: immunosuppressive therapy; LV: left ventricular; M: mitral; Mo: months; MP: mitral prothesis; MR: mitral regurgitation; MS: mitral stenosis; MVR: mitral valve replacement.

Half the valvular lesions were present at initial presentation and when the diagnosis of vasculitis was made \[[@B2],[@B6],[@B7],[@B9],[@B12],[@B14],[@B16]-[@B18]\]. In six of the ten remaining cases, the valvular disease occurred while the patient was on immunosuppressant drugs \[[@B5],[@B8],[@B10],[@B11],[@B13],[@B19]\]. In two of these five cases, the onset was less than a week after the treatment was initiated suggesting that the pathological process was already taking place when the drugs were started \[[@B8],[@B19]\]. In only four cases valvular disease began more than a year after the first signs of the vasculitis \[[@B3],[@B4],[@B10],[@B20]\].

A valve replacement was required in most cases \[[@B3],[@B4],[@B6],[@B7],[@B9],[@B10],[@B12],[@B13],[@B19],[@B20]\]. In only two cases did immunosuppressive therapy allow a complete resolution of the valvular lesions \[[@B8],[@B9]\]; and in one of these \[[@B9]\] the patient had nonetheless to undergo an aortic valve replacement because of secondary left ventricular dilatation and a shrunken leaflet.

The pathological findings were nonspecific in almost all cases; i.e. showing inflammation and/or scarring without abscess, giant cells, vasculitis, or granuloma. In two cases, granuloma, necrosis and/or micro abscess were described in the valvular tissue \[[@B4],[@B12]\].

To conclude, although it might be underdiagnosed due to the lack of patent clinical signs and the absence of systematic screening, valvular involvement in ANCA-associated systemic vasculitides is rarely reported. Most of these valvular lesions are due to Wegener\'s granulomatosis and half are present when the diagnosis of vasculitis is made. The valvular lesion is usually unique, aortic regurgitation being the most frequent type, and often requires valve replacement in the months that follow its discovery.
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